| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 207 | 2026 | 1836 | 27.410 |
Why?
|
| Testicular Neoplasms | 43 | 2026 | 126 | 12.530 |
Why?
|
| Prostate-Specific Antigen | 64 | 2026 | 354 | 12.050 |
Why?
|
| Prostatectomy | 72 | 2026 | 490 | 10.510 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 26 | 2026 | 63 | 7.290 |
Why?
|
| Prostate | 43 | 2025 | 434 | 6.230 |
Why?
|
| Lymph Node Excision | 27 | 2026 | 238 | 5.350 |
Why?
|
| Nephrectomy | 33 | 2025 | 290 | 5.110 |
Why?
|
| Kidney Neoplasms | 38 | 2025 | 556 | 5.080 |
Why?
|
| Watchful Waiting | 16 | 2025 | 73 | 4.700 |
Why?
|
| Neoplasm Grading | 33 | 2026 | 422 | 4.320 |
Why?
|
| Male | 310 | 2026 | 47109 | 4.270 |
Why?
|
| Early Detection of Cancer | 23 | 2026 | 550 | 3.350 |
Why?
|
| Carcinoma, Renal Cell | 21 | 2025 | 384 | 3.070 |
Why?
|
| Humans | 333 | 2026 | 98135 | 2.990 |
Why?
|
| Robotic Surgical Procedures | 11 | 2026 | 411 | 2.670 |
Why?
|
| Neoplasm Staging | 58 | 2025 | 2080 | 2.480 |
Why?
|
| Neoplasm Recurrence, Local | 27 | 2026 | 1535 | 2.400 |
Why?
|
| Laparoscopy | 21 | 2025 | 792 | 2.380 |
Why?
|
| Laser Therapy | 13 | 2025 | 150 | 2.230 |
Why?
|
| Biomarkers, Tumor | 23 | 2026 | 1764 | 2.220 |
Why?
|
| Biopsy | 37 | 2026 | 1224 | 2.220 |
Why?
|
| Magnetic Resonance Imaging | 41 | 2026 | 3618 | 2.160 |
Why?
|
| Retroperitoneal Space | 18 | 2026 | 43 | 2.160 |
Why?
|
| Aged | 128 | 2026 | 21760 | 2.130 |
Why?
|
| Seminoma | 7 | 2025 | 15 | 2.090 |
Why?
|
| Organ Transplantation | 6 | 2024 | 306 | 2.040 |
Why?
|
| Middle Aged | 145 | 2026 | 29442 | 2.020 |
Why?
|
| Magnetic Resonance Imaging, Interventional | 9 | 2020 | 34 | 2.000 |
Why?
|
| Population Surveillance | 7 | 2019 | 218 | 1.900 |
Why?
|
| Orchiectomy | 12 | 2025 | 64 | 1.810 |
Why?
|
| Urinary Incontinence | 9 | 2017 | 225 | 1.800 |
Why?
|
| Image-Guided Biopsy | 13 | 2025 | 81 | 1.770 |
Why?
|
| Quality of Life | 15 | 2025 | 1895 | 1.750 |
Why?
|
| Lymph Nodes | 8 | 2025 | 560 | 1.550 |
Why?
|
| Adenocarcinoma | 5 | 2023 | 1211 | 1.520 |
Why?
|
| SEER Program | 10 | 2024 | 243 | 1.520 |
Why?
|
| Ablation Techniques | 5 | 2019 | 52 | 1.500 |
Why?
|
| Mass Screening | 11 | 2023 | 745 | 1.470 |
Why?
|
| Retrospective Studies | 66 | 2026 | 10962 | 1.460 |
Why?
|
| Prognosis | 38 | 2024 | 4116 | 1.450 |
Why?
|
| Life Expectancy | 4 | 2017 | 93 | 1.430 |
Why?
|
| Risk Assessment | 36 | 2026 | 2585 | 1.420 |
Why?
|
| Postoperative Hemorrhage | 3 | 2025 | 55 | 1.400 |
Why?
|
| Teratoma | 6 | 2023 | 56 | 1.340 |
Why?
|
| Chemotherapy, Adjuvant | 8 | 2024 | 525 | 1.320 |
Why?
|
| Kallikreins | 8 | 2025 | 47 | 1.280 |
Why?
|
| Lymphatic Metastasis | 19 | 2025 | 520 | 1.280 |
Why?
|
| Treatment Outcome | 54 | 2026 | 9713 | 1.250 |
Why?
|
| Retroperitoneal Neoplasms | 5 | 2018 | 42 | 1.240 |
Why?
|
| Urology | 6 | 2023 | 144 | 1.220 |
Why?
|
| Androgen Antagonists | 8 | 2026 | 157 | 1.210 |
Why?
|
| Patient Selection | 13 | 2021 | 725 | 1.200 |
Why?
|
| Practice Guidelines as Topic | 8 | 2021 | 1109 | 1.170 |
Why?
|
| Predictive Value of Tests | 26 | 2025 | 1784 | 1.140 |
Why?
|
| Disease Management | 5 | 2019 | 377 | 1.120 |
Why?
|
| Robotics | 12 | 2015 | 272 | 1.110 |
Why?
|
| Photochemotherapy | 7 | 2018 | 101 | 1.100 |
Why?
|
| Prospective Studies | 32 | 2025 | 4825 | 1.080 |
Why?
|
| Biopsy, Needle | 14 | 2014 | 226 | 1.080 |
Why?
|
| Blood Loss, Surgical | 3 | 2025 | 139 | 1.080 |
Why?
|
| United States | 33 | 2026 | 8193 | 1.070 |
Why?
|
| Ultrasound, High-Intensity Focused, Transrectal | 6 | 2025 | 7 | 1.050 |
Why?
|
| Surgery, Computer-Assisted | 6 | 2025 | 121 | 0.990 |
Why?
|
| Radiotherapy, Adjuvant | 7 | 2026 | 323 | 0.950 |
Why?
|
| Warm Ischemia | 5 | 2014 | 34 | 0.940 |
Why?
|
| Adult | 67 | 2026 | 29564 | 0.920 |
Why?
|
| Risk Factors | 27 | 2024 | 6232 | 0.900 |
Why?
|
| Hemostatics | 1 | 2025 | 64 | 0.890 |
Why?
|
| Cryosurgery | 7 | 2018 | 76 | 0.880 |
Why?
|
| Kidney | 10 | 2021 | 1123 | 0.870 |
Why?
|
| Combined Modality Therapy | 15 | 2026 | 1751 | 0.860 |
Why?
|
| Precancerous Conditions | 1 | 2026 | 218 | 0.860 |
Why?
|
| Incidence | 18 | 2022 | 1777 | 0.850 |
Why?
|
| Consensus | 7 | 2026 | 315 | 0.820 |
Why?
|
| Salvage Therapy | 6 | 2017 | 239 | 0.820 |
Why?
|
| Practice Patterns, Physicians' | 5 | 2020 | 658 | 0.810 |
Why?
|
| Disease-Free Survival | 15 | 2024 | 1193 | 0.780 |
Why?
|
| Epididymis | 6 | 2018 | 19 | 0.770 |
Why?
|
| Urinary Bladder Neoplasms | 10 | 2021 | 401 | 0.760 |
Why?
|
| Cohort Studies | 22 | 2025 | 3213 | 0.750 |
Why?
|
| Neoplasm Invasiveness | 13 | 2016 | 582 | 0.700 |
Why?
|
| Aged, 80 and over | 27 | 2025 | 7387 | 0.700 |
Why?
|
| Time Factors | 24 | 2025 | 5576 | 0.680 |
Why?
|
| Glomerular Filtration Rate | 8 | 2014 | 299 | 0.680 |
Why?
|
| Erectile Dysfunction | 3 | 2014 | 81 | 0.680 |
Why?
|
| Logistic Models | 10 | 2023 | 1275 | 0.680 |
Why?
|
| Carcinoma, Transitional Cell | 7 | 2021 | 158 | 0.670 |
Why?
|
| Tumor Burden | 7 | 2021 | 333 | 0.660 |
Why?
|
| Proportional Hazards Models | 13 | 2022 | 922 | 0.660 |
Why?
|
| Seminal Vesicles | 5 | 2022 | 40 | 0.640 |
Why?
|
| Gonadotropin-Releasing Hormone | 2 | 2024 | 100 | 0.610 |
Why?
|
| Age Factors | 13 | 2017 | 1967 | 0.600 |
Why?
|
| Terminology as Topic | 2 | 2021 | 225 | 0.600 |
Why?
|
| Induction Chemotherapy | 1 | 2020 | 151 | 0.590 |
Why?
|
| Rectum | 3 | 2018 | 150 | 0.580 |
Why?
|
| Genes, Neoplasm | 1 | 2019 | 39 | 0.580 |
Why?
|
| Postoperative Complications | 9 | 2020 | 2680 | 0.570 |
Why?
|
| Lost to Follow-Up | 1 | 2018 | 17 | 0.560 |
Why?
|
| Multivariate Analysis | 14 | 2018 | 1009 | 0.560 |
Why?
|
| Clinical Protocols | 2 | 2019 | 162 | 0.560 |
Why?
|
| Aorta, Abdominal | 1 | 2018 | 57 | 0.560 |
Why?
|
| Intraoperative Complications | 2 | 2018 | 194 | 0.550 |
Why?
|
| Survival Rate | 13 | 2026 | 2041 | 0.550 |
Why?
|
| Guideline Adherence | 3 | 2016 | 250 | 0.540 |
Why?
|
| High-Intensity Focused Ultrasound Ablation | 5 | 2025 | 54 | 0.540 |
Why?
|
| Young Adult | 17 | 2025 | 7511 | 0.530 |
Why?
|
| Neoplasms | 3 | 2024 | 3334 | 0.530 |
Why?
|
| Insurance, Health | 2 | 2017 | 186 | 0.530 |
Why?
|
| Acinar Cells | 1 | 2017 | 8 | 0.510 |
Why?
|
| Vena Cava, Inferior | 1 | 2018 | 140 | 0.510 |
Why?
|
| alpha-Fetoproteins | 1 | 2017 | 48 | 0.500 |
Why?
|
| 5-alpha Reductase Inhibitors | 2 | 2024 | 12 | 0.500 |
Why?
|
| Pathologists | 1 | 2017 | 44 | 0.490 |
Why?
|
| Immunosuppressive Agents | 2 | 2024 | 1013 | 0.480 |
Why?
|
| Cold Ischemia | 2 | 2014 | 22 | 0.480 |
Why?
|
| Public Policy | 1 | 2016 | 61 | 0.480 |
Why?
|
| Follow-Up Studies | 19 | 2026 | 4026 | 0.470 |
Why?
|
| Biomarkers | 6 | 2021 | 2022 | 0.460 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2022 | 194 | 0.460 |
Why?
|
| Carcinoma, Ductal | 1 | 2015 | 20 | 0.450 |
Why?
|
| Anti-Bacterial Agents | 2 | 2013 | 881 | 0.450 |
Why?
|
| Kidney Diseases | 3 | 2010 | 314 | 0.450 |
Why?
|
| Carcinoma, Acinar Cell | 1 | 2015 | 16 | 0.450 |
Why?
|
| Medically Uninsured | 1 | 2015 | 72 | 0.450 |
Why?
|
| Medicare | 2 | 2020 | 466 | 0.450 |
Why?
|
| Minimally Invasive Surgical Procedures | 4 | 2014 | 309 | 0.450 |
Why?
|
| Aspirin | 1 | 2016 | 169 | 0.440 |
Why?
|
| Conversion to Open Surgery | 1 | 2015 | 11 | 0.440 |
Why?
|
| Contrast Media | 12 | 2019 | 1011 | 0.440 |
Why?
|
| Goserelin | 1 | 2014 | 5 | 0.430 |
Why?
|
| Tosyl Compounds | 1 | 2014 | 14 | 0.430 |
Why?
|
| Health Policy | 1 | 2016 | 216 | 0.420 |
Why?
|
| Anilides | 1 | 2014 | 50 | 0.420 |
Why?
|
| Cost-Benefit Analysis | 1 | 2017 | 523 | 0.410 |
Why?
|
| Carboplatin | 1 | 2015 | 331 | 0.410 |
Why?
|
| Nitriles | 1 | 2014 | 171 | 0.400 |
Why?
|
| Surgeons | 1 | 2018 | 325 | 0.400 |
Why?
|
| Decision Making | 2 | 2022 | 686 | 0.400 |
Why?
|
| Ciprofloxacin | 1 | 2013 | 24 | 0.390 |
Why?
|
| Intestinal Diseases | 1 | 2014 | 84 | 0.390 |
Why?
|
| Female | 47 | 2025 | 51570 | 0.390 |
Why?
|
| Survival Analysis | 13 | 2019 | 1527 | 0.390 |
Why?
|
| Neoplasm, Residual | 8 | 2026 | 206 | 0.390 |
Why?
|
| Androgens | 5 | 2024 | 164 | 0.380 |
Why?
|
| Pelvis | 4 | 2025 | 106 | 0.380 |
Why?
|
| Genetic Testing | 3 | 2025 | 594 | 0.380 |
Why?
|
| Brachytherapy | 5 | 2017 | 139 | 0.370 |
Why?
|
| Sensitivity and Specificity | 12 | 2019 | 1948 | 0.360 |
Why?
|
| Nomograms | 3 | 2011 | 34 | 0.360 |
Why?
|
| Pelvic Neoplasms | 2 | 2025 | 43 | 0.360 |
Why?
|
| Feasibility Studies | 7 | 2025 | 803 | 0.360 |
Why?
|
| Developed Countries | 1 | 2012 | 25 | 0.360 |
Why?
|
| Databases, Factual | 6 | 2016 | 1090 | 0.360 |
Why?
|
| Developing Countries | 1 | 2012 | 101 | 0.340 |
Why?
|
| Clinical Trials as Topic | 5 | 2019 | 1131 | 0.340 |
Why?
|
| Medical Oncology | 4 | 2025 | 421 | 0.330 |
Why?
|
| Epithelial Cells | 5 | 2018 | 709 | 0.320 |
Why?
|
| Forecasting | 3 | 2019 | 295 | 0.320 |
Why?
|
| Global Health | 1 | 2012 | 215 | 0.320 |
Why?
|
| Finasteride | 2 | 2009 | 8 | 0.310 |
Why?
|
| Positron-Emission Tomography | 2 | 2025 | 354 | 0.310 |
Why?
|
| Neoplasm Metastasis | 10 | 2025 | 1089 | 0.310 |
Why?
|
| Sentinel Surveillance | 1 | 2009 | 23 | 0.300 |
Why?
|
| Tomography, X-Ray Computed | 9 | 2025 | 2668 | 0.300 |
Why?
|
| Kidney Tubules, Collecting | 1 | 2009 | 24 | 0.300 |
Why?
|
| Gadolinium DTPA | 7 | 2014 | 239 | 0.300 |
Why?
|
| Sus scrofa | 1 | 2009 | 49 | 0.300 |
Why?
|
| Treatment Failure | 2 | 2014 | 300 | 0.300 |
Why?
|
| Germ-Line Mutation | 2 | 2025 | 402 | 0.290 |
Why?
|
| Systems Theory | 1 | 2009 | 2 | 0.290 |
Why?
|
| Sutures | 1 | 2009 | 59 | 0.290 |
Why?
|
| Bucrylate | 1 | 2008 | 2 | 0.290 |
Why?
|
| Image Enhancement | 4 | 2018 | 503 | 0.290 |
Why?
|
| Disease Progression | 10 | 2018 | 1610 | 0.290 |
Why?
|
| Tissue Adhesives | 1 | 2008 | 22 | 0.290 |
Why?
|
| Chemoprevention | 1 | 2009 | 93 | 0.280 |
Why?
|
| Enzyme Inhibitors | 2 | 2009 | 642 | 0.280 |
Why?
|
| Environmental Exposure | 1 | 2012 | 405 | 0.280 |
Why?
|
| Hospitalization | 1 | 2014 | 991 | 0.270 |
Why?
|
| Breast Neoplasms | 1 | 2022 | 3272 | 0.270 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2026 | 159 | 0.270 |
Why?
|
| Research Design | 3 | 2019 | 660 | 0.270 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2019 | 903 | 0.270 |
Why?
|
| Ultrasonography, Interventional | 4 | 2018 | 126 | 0.260 |
Why?
|
| Ureteral Neoplasms | 3 | 2012 | 13 | 0.260 |
Why?
|
| Odds Ratio | 3 | 2017 | 726 | 0.260 |
Why?
|
| Penile Erection | 2 | 2017 | 22 | 0.250 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 6 | 2019 | 304 | 0.250 |
Why?
|
| Nuclear Proteins | 2 | 2014 | 750 | 0.250 |
Why?
|
| Recurrence | 6 | 2023 | 1254 | 0.250 |
Why?
|
| Genomics | 3 | 2025 | 898 | 0.240 |
Why?
|
| Kidney Failure, Chronic | 1 | 2010 | 445 | 0.230 |
Why?
|
| Europe | 4 | 2020 | 356 | 0.230 |
Why?
|
| Radiotherapy, Intensity-Modulated | 2 | 2019 | 200 | 0.230 |
Why?
|
| Medical Overuse | 1 | 2025 | 32 | 0.230 |
Why?
|
| Perioperative Care | 2 | 2019 | 198 | 0.230 |
Why?
|
| Cryptorchidism | 1 | 2005 | 12 | 0.220 |
Why?
|
| Genital Neoplasms, Male | 1 | 2005 | 9 | 0.220 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2026 | 133 | 0.210 |
Why?
|
| Image Interpretation, Computer-Assisted | 5 | 2018 | 642 | 0.210 |
Why?
|
| Comorbidity | 3 | 2019 | 1031 | 0.210 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2026 | 2658 | 0.210 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2025 | 146 | 0.210 |
Why?
|
| Sperm Retrieval | 1 | 2024 | 3 | 0.210 |
Why?
|
| Nanostructures | 1 | 2025 | 93 | 0.210 |
Why?
|
| Kidney Function Tests | 4 | 2013 | 122 | 0.210 |
Why?
|
| Sarcoma, Myeloid | 1 | 2004 | 14 | 0.210 |
Why?
|
| Analysis of Variance | 6 | 2014 | 889 | 0.210 |
Why?
|
| Propensity Score | 2 | 2026 | 213 | 0.210 |
Why?
|
| Vascular Neoplasms | 1 | 2004 | 21 | 0.200 |
Why?
|
| Fructose | 1 | 2004 | 38 | 0.200 |
Why?
|
| Urinary Calculi | 1 | 2004 | 45 | 0.200 |
Why?
|
| Radiopharmaceuticals | 1 | 2025 | 217 | 0.200 |
Why?
|
| Radiotherapy | 2 | 2016 | 325 | 0.200 |
Why?
|
| Fertility Preservation | 1 | 2024 | 26 | 0.200 |
Why?
|
| Electrochemotherapy | 3 | 2018 | 4 | 0.200 |
Why?
|
| Risk | 2 | 2015 | 660 | 0.200 |
Why?
|
| Adolescent | 9 | 2025 | 10097 | 0.200 |
Why?
|
| Preoperative Care | 5 | 2019 | 418 | 0.190 |
Why?
|
| Emphysema | 1 | 2003 | 24 | 0.190 |
Why?
|
| Length of Stay | 3 | 2016 | 878 | 0.190 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2003 | 41 | 0.190 |
Why?
|
| Antineoplastic Agents | 5 | 2019 | 2373 | 0.190 |
Why?
|
| Penis | 1 | 2003 | 65 | 0.190 |
Why?
|
| Lymphadenopathy | 1 | 2023 | 20 | 0.190 |
Why?
|
| Health Surveys | 2 | 2015 | 254 | 0.190 |
Why?
|
| Urologists | 1 | 2023 | 39 | 0.190 |
Why?
|
| Anticonvulsants | 1 | 2004 | 132 | 0.190 |
Why?
|
| Kidney Transplantation | 2 | 2024 | 939 | 0.190 |
Why?
|
| Guanidines | 1 | 2022 | 34 | 0.190 |
Why?
|
| Surveys and Questionnaires | 7 | 2022 | 3022 | 0.180 |
Why?
|
| Transplant Recipients | 1 | 2024 | 182 | 0.180 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2005 | 283 | 0.180 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2014 | 271 | 0.180 |
Why?
|
| False Positive Reactions | 2 | 2015 | 215 | 0.180 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2024 | 117 | 0.180 |
Why?
|
| Perception | 1 | 2023 | 187 | 0.180 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2026 | 1012 | 0.180 |
Why?
|
| Cause of Death | 2 | 2014 | 278 | 0.180 |
Why?
|
| Angiomyolipoma | 1 | 2021 | 15 | 0.170 |
Why?
|
| Pulmonary Artery | 1 | 2004 | 342 | 0.170 |
Why?
|
| Lipoma | 1 | 2001 | 23 | 0.170 |
Why?
|
| Primary Cell Culture | 3 | 2018 | 84 | 0.170 |
Why?
|
| Registries | 3 | 2019 | 1122 | 0.170 |
Why?
|
| Radiosurgery | 1 | 2025 | 351 | 0.170 |
Why?
|
| Pulmonary Embolism | 1 | 2004 | 234 | 0.170 |
Why?
|
| Delphi Technique | 3 | 2019 | 181 | 0.170 |
Why?
|
| Ureteroscopy | 2 | 2012 | 35 | 0.170 |
Why?
|
| Receptors, Androgen | 2 | 2018 | 125 | 0.170 |
Why?
|
| Hydronephrosis | 2 | 2011 | 23 | 0.170 |
Why?
|
| Operative Time | 3 | 2016 | 174 | 0.160 |
Why?
|
| Margins of Excision | 2 | 2022 | 49 | 0.160 |
Why?
|
| Piperazines | 1 | 2022 | 306 | 0.160 |
Why?
|
| Body Mass Index | 2 | 2014 | 850 | 0.160 |
Why?
|
| Societies, Medical | 3 | 2026 | 682 | 0.160 |
Why?
|
| Hypersensitivity | 1 | 2022 | 166 | 0.160 |
Why?
|
| Urinary Bladder | 3 | 2015 | 262 | 0.160 |
Why?
|
| Interdisciplinary Studies | 1 | 2019 | 19 | 0.150 |
Why?
|
| Gene Regulatory Networks | 3 | 2018 | 337 | 0.150 |
Why?
|
| Hyperthermia, Induced | 1 | 2020 | 77 | 0.150 |
Why?
|
| Pathology, Molecular | 1 | 2019 | 35 | 0.150 |
Why?
|
| Long Term Adverse Effects | 1 | 2019 | 7 | 0.150 |
Why?
|
| Urinalysis | 1 | 2019 | 34 | 0.150 |
Why?
|
| Animals | 11 | 2025 | 28902 | 0.150 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2019 | 237 | 0.150 |
Why?
|
| Mesothelioma | 1 | 2022 | 346 | 0.150 |
Why?
|
| Venae Cavae | 1 | 2019 | 12 | 0.150 |
Why?
|
| Prostatic Hyperplasia | 2 | 2018 | 104 | 0.150 |
Why?
|
| Survivors | 1 | 2020 | 213 | 0.150 |
Why?
|
| Jordan | 1 | 2018 | 12 | 0.140 |
Why?
|
| Linear Models | 4 | 2014 | 424 | 0.140 |
Why?
|
| Patients | 1 | 2019 | 105 | 0.140 |
Why?
|
| Immunohistochemistry | 7 | 2013 | 1815 | 0.140 |
Why?
|
| Dissection | 2 | 2017 | 48 | 0.140 |
Why?
|
| United States Food and Drug Administration | 1 | 2019 | 164 | 0.140 |
Why?
|
| Ultrasonography | 2 | 2013 | 720 | 0.140 |
Why?
|
| Music Therapy | 1 | 2018 | 2 | 0.140 |
Why?
|
| Journalism, Medical | 1 | 1998 | 6 | 0.140 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 1 | 2018 | 17 | 0.140 |
Why?
|
| Transplantation Conditioning | 1 | 2020 | 388 | 0.140 |
Why?
|
| Gadolinium | 1 | 2018 | 95 | 0.140 |
Why?
|
| Emotions | 1 | 2022 | 387 | 0.140 |
Why?
|
| Radiation Injuries | 1 | 2019 | 160 | 0.130 |
Why?
|
| Transcriptional Regulator ERG | 2 | 2015 | 17 | 0.130 |
Why?
|
| Quality Improvement | 2 | 2019 | 520 | 0.130 |
Why?
|
| Employment | 1 | 1998 | 66 | 0.130 |
Why?
|
| Monitoring, Physiologic | 2 | 2009 | 263 | 0.130 |
Why?
|
| Models, Educational | 1 | 2017 | 47 | 0.130 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2018 | 168 | 0.130 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2018 | 153 | 0.130 |
Why?
|
| Decision Support Techniques | 1 | 2019 | 194 | 0.130 |
Why?
|
| Vascular Surgical Procedures | 1 | 2018 | 166 | 0.130 |
Why?
|
| Cross-Sectional Studies | 2 | 2014 | 2037 | 0.120 |
Why?
|
| Urination Disorders | 2 | 2015 | 52 | 0.120 |
Why?
|
| Genome-Wide Association Study | 1 | 2025 | 1850 | 0.120 |
Why?
|
| Hematologic Neoplasms | 1 | 2020 | 383 | 0.120 |
Why?
|
| Urination | 1 | 2016 | 39 | 0.120 |
Why?
|
| Venous Thrombosis | 1 | 2019 | 264 | 0.120 |
Why?
|
| Hepatocyte Nuclear Factor 1 | 1 | 2016 | 30 | 0.120 |
Why?
|
| Prednisone | 3 | 2026 | 251 | 0.120 |
Why?
|
| Testis | 1 | 2016 | 150 | 0.120 |
Why?
|
| Device Approval | 1 | 2015 | 15 | 0.120 |
Why?
|
| Melanoma | 1 | 2020 | 524 | 0.120 |
Why?
|
| Regulatory Elements, Transcriptional | 1 | 2016 | 48 | 0.120 |
Why?
|
| RNA, Messenger | 3 | 2019 | 2063 | 0.120 |
Why?
|
| Creatinine | 2 | 2014 | 313 | 0.110 |
Why?
|
| Spermatozoa | 1 | 2015 | 69 | 0.110 |
Why?
|
| Simulation Training | 1 | 2017 | 118 | 0.110 |
Why?
|
| Cystadenoma | 1 | 2015 | 18 | 0.110 |
Why?
|
| Selection Bias | 1 | 2015 | 37 | 0.110 |
Why?
|
| Corneal Injuries | 1 | 2015 | 8 | 0.110 |
Why?
|
| Statistics, Nonparametric | 2 | 2013 | 303 | 0.110 |
Why?
|
| Protein Precursors | 1 | 2015 | 133 | 0.110 |
Why?
|
| Abiraterone Acetate | 2 | 2026 | 14 | 0.110 |
Why?
|
| Anxiety | 1 | 2018 | 370 | 0.110 |
Why?
|
| Probability | 3 | 2013 | 356 | 0.110 |
Why?
|
| Blood Transfusion | 1 | 2016 | 180 | 0.110 |
Why?
|
| Serine Endopeptidases | 1 | 2015 | 154 | 0.110 |
Why?
|
| Trans-Activators | 2 | 2015 | 447 | 0.110 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2008 | 1394 | 0.110 |
Why?
|
| Technology Assessment, Biomedical | 1 | 2014 | 24 | 0.110 |
Why?
|
| Carrier Proteins | 2 | 2008 | 667 | 0.110 |
Why?
|
| Anatomic Landmarks | 1 | 2014 | 30 | 0.100 |
Why?
|
| Sex Factors | 2 | 2015 | 1138 | 0.100 |
Why?
|
| Organ Sparing Treatments | 1 | 2014 | 52 | 0.100 |
Why?
|
| Immunity, Innate | 1 | 2018 | 481 | 0.100 |
Why?
|
| Child | 3 | 2020 | 7699 | 0.100 |
Why?
|
| Carcinoma, Small Cell | 1 | 2014 | 116 | 0.100 |
Why?
|
| Interviews as Topic | 1 | 2015 | 387 | 0.100 |
Why?
|
| Mental Recall | 1 | 2015 | 173 | 0.100 |
Why?
|
| Hysterectomy | 1 | 2015 | 174 | 0.100 |
Why?
|
| MicroRNAs | 1 | 2018 | 604 | 0.100 |
Why?
|
| Lymphocele | 1 | 2013 | 7 | 0.100 |
Why?
|
| Antigens, Neoplasm | 1 | 2015 | 361 | 0.100 |
Why?
|
| Hematuria | 3 | 2022 | 51 | 0.100 |
Why?
|
| Algorithms | 4 | 2019 | 2009 | 0.100 |
Why?
|
| Mortality | 1 | 2014 | 159 | 0.100 |
Why?
|
| Peripheral Nerve Injuries | 1 | 2013 | 22 | 0.100 |
Why?
|
| Confidence Intervals | 2 | 2013 | 220 | 0.090 |
Why?
|
| Cell Proliferation | 2 | 2017 | 1790 | 0.090 |
Why?
|
| Mannitol | 1 | 2012 | 49 | 0.090 |
Why?
|
| ROC Curve | 4 | 2018 | 795 | 0.090 |
Why?
|
| Activities of Daily Living | 1 | 2014 | 214 | 0.090 |
Why?
|
| Monte Carlo Method | 1 | 2013 | 194 | 0.090 |
Why?
|
| Equipment Design | 1 | 2013 | 427 | 0.090 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2019 | 1307 | 0.090 |
Why?
|
| Chicago | 1 | 2016 | 1513 | 0.090 |
Why?
|
| Social Media | 1 | 2014 | 118 | 0.090 |
Why?
|
| Advisory Committees | 1 | 2012 | 95 | 0.090 |
Why?
|
| Health Status | 1 | 2014 | 385 | 0.090 |
Why?
|
| Urothelium | 1 | 2012 | 67 | 0.090 |
Why?
|
| Mice, Nude | 3 | 2014 | 830 | 0.090 |
Why?
|
| Urography | 2 | 2009 | 30 | 0.090 |
Why?
|
| Reoperation | 2 | 2018 | 726 | 0.090 |
Why?
|
| Americas | 1 | 2011 | 21 | 0.090 |
Why?
|
| Clinical Decision-Making | 3 | 2019 | 305 | 0.090 |
Why?
|
| Neovascularization, Pathologic | 2 | 2011 | 356 | 0.090 |
Why?
|
| Patient Safety | 1 | 2014 | 235 | 0.080 |
Why?
|
| Healthcare Disparities | 1 | 2017 | 539 | 0.080 |
Why?
|
| Asia | 1 | 2011 | 109 | 0.080 |
Why?
|
| Africa | 1 | 2011 | 111 | 0.080 |
Why?
|
| Australia | 1 | 2011 | 125 | 0.080 |
Why?
|
| Physicians | 1 | 1998 | 685 | 0.080 |
Why?
|
| Cystectomy | 2 | 2010 | 124 | 0.080 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2014 | 269 | 0.080 |
Why?
|
| Repressor Proteins | 1 | 2014 | 447 | 0.080 |
Why?
|
| Diagnosis, Differential | 4 | 2021 | 1568 | 0.080 |
Why?
|
| Mathematics | 1 | 2010 | 178 | 0.080 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2013 | 339 | 0.080 |
Why?
|
| Proteins | 1 | 2015 | 804 | 0.080 |
Why?
|
| Urinary Reservoirs, Continent | 1 | 2010 | 14 | 0.080 |
Why?
|
| Trauma, Nervous System | 1 | 2009 | 10 | 0.080 |
Why?
|
| Ejaculation | 1 | 2009 | 9 | 0.080 |
Why?
|
| Medical Illustration | 1 | 2009 | 14 | 0.080 |
Why?
|
| Radiographic Image Enhancement | 1 | 2012 | 449 | 0.080 |
Why?
|
| Urine | 1 | 2010 | 91 | 0.080 |
Why?
|
| Internship and Residency | 2 | 2017 | 1123 | 0.080 |
Why?
|
| Calreticulin | 1 | 2009 | 16 | 0.080 |
Why?
|
| Smoking | 1 | 2014 | 674 | 0.080 |
Why?
|
| Urinary Diversion | 1 | 2010 | 41 | 0.080 |
Why?
|
| Postoperative Period | 3 | 2015 | 322 | 0.080 |
Why?
|
| Credentialing | 1 | 2009 | 16 | 0.070 |
Why?
|
| Gene Expression Profiling | 4 | 2018 | 1566 | 0.070 |
Why?
|
| Obesity | 2 | 2014 | 1061 | 0.070 |
Why?
|
| Living Donors | 1 | 2012 | 375 | 0.070 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2003 | 461 | 0.070 |
Why?
|
| Depression | 1 | 2014 | 615 | 0.070 |
Why?
|
| Socioeconomic Factors | 1 | 2012 | 663 | 0.070 |
Why?
|
| Nephrons | 1 | 2009 | 16 | 0.070 |
Why?
|
| Dutasteride | 1 | 2009 | 5 | 0.070 |
Why?
|
| Azasteroids | 1 | 2009 | 5 | 0.070 |
Why?
|
| Pilot Projects | 2 | 2025 | 977 | 0.070 |
Why?
|
| 3-Oxo-5-alpha-Steroid 4-Dehydrogenase | 1 | 2009 | 9 | 0.070 |
Why?
|
| Residence Characteristics | 1 | 2011 | 224 | 0.070 |
Why?
|
| Validation Studies as Topic | 1 | 2009 | 20 | 0.070 |
Why?
|
| Fascia | 1 | 2009 | 32 | 0.070 |
Why?
|
| Bacteriochlorophylls | 1 | 2008 | 1 | 0.070 |
Why?
|
| Cell Line, Tumor | 4 | 2009 | 2888 | 0.070 |
Why?
|
| Multicenter Studies as Topic | 1 | 2009 | 200 | 0.070 |
Why?
|
| Gene Expression Regulation | 4 | 2018 | 2023 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2008 | 26 | 0.070 |
Why?
|
| Primary Prevention | 1 | 2009 | 91 | 0.070 |
Why?
|
| Prostatic Secretory Proteins | 1 | 2007 | 1 | 0.070 |
Why?
|
| Seminal Plasma Proteins | 1 | 2007 | 2 | 0.070 |
Why?
|
| Salivary Proteins and Peptides | 1 | 2007 | 5 | 0.070 |
Why?
|
| Overweight | 1 | 2008 | 123 | 0.070 |
Why?
|
| Urologic Surgical Procedures | 1 | 2009 | 154 | 0.070 |
Why?
|
| Neoplastic Stem Cells | 1 | 2009 | 189 | 0.060 |
Why?
|
| Chronic Disease | 1 | 2010 | 985 | 0.060 |
Why?
|
| Gene Rearrangement | 1 | 2008 | 175 | 0.060 |
Why?
|
| Swine | 1 | 2008 | 593 | 0.060 |
Why?
|
| Dioxygenases | 1 | 2007 | 87 | 0.060 |
Why?
|
| Radiotherapy, Conformal | 1 | 2007 | 88 | 0.060 |
Why?
|
| Survival | 1 | 2006 | 22 | 0.060 |
Why?
|
| Sweden | 1 | 2026 | 48 | 0.060 |
Why?
|
| Reproducibility of Results | 4 | 2014 | 2787 | 0.060 |
Why?
|
| Thiohydantoins | 1 | 2026 | 4 | 0.060 |
Why?
|
| Carcinoma in Situ | 1 | 2006 | 54 | 0.060 |
Why?
|
| Gene Fusion | 2 | 2021 | 41 | 0.060 |
Why?
|
| BCG Vaccine | 1 | 2006 | 43 | 0.060 |
Why?
|
| Catheter Ablation | 3 | 2016 | 381 | 0.060 |
Why?
|
| Thromboembolism | 1 | 2006 | 124 | 0.060 |
Why?
|
| Immunocompromised Host | 1 | 2006 | 139 | 0.060 |
Why?
|
| Theranostic Nanomedicine | 1 | 2025 | 2 | 0.060 |
Why?
|
| Adjuvants, Immunologic | 1 | 2006 | 176 | 0.060 |
Why?
|
| Steroids | 1 | 2006 | 168 | 0.060 |
Why?
|
| Transition Elements | 1 | 2025 | 4 | 0.060 |
Why?
|
| Neoadjuvant Therapy | 2 | 2019 | 478 | 0.060 |
Why?
|
| Nitrites | 1 | 2025 | 34 | 0.060 |
Why?
|
| Evidence-Based Medicine | 1 | 2008 | 480 | 0.060 |
Why?
|
| Kinetics | 1 | 2007 | 1476 | 0.050 |
Why?
|
| Transplantation, Heterologous | 1 | 2006 | 375 | 0.050 |
Why?
|
| Costs and Cost Analysis | 1 | 2005 | 155 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2025 | 2558 | 0.050 |
Why?
|
| Cystitis | 1 | 2004 | 12 | 0.050 |
Why?
|
| Cardiovascular Diseases | 1 | 2011 | 802 | 0.050 |
Why?
|
| Leuprolide | 1 | 2024 | 34 | 0.050 |
Why?
|
| Cell Cycle | 1 | 2006 | 518 | 0.050 |
Why?
|
| Cell Nucleolus | 1 | 2004 | 25 | 0.050 |
Why?
|
| Castration | 1 | 2024 | 32 | 0.050 |
Why?
|
| Daunorubicin | 1 | 2004 | 77 | 0.050 |
Why?
|
| Plasma Cells | 1 | 2004 | 89 | 0.050 |
Why?
|
| Coitus | 1 | 2003 | 20 | 0.050 |
Why?
|
| Rupture | 1 | 2003 | 58 | 0.050 |
Why?
|
| Cryopreservation | 1 | 2024 | 74 | 0.050 |
Why?
|
| Academic Medical Centers | 1 | 2026 | 413 | 0.050 |
Why?
|
| Methotrexate | 1 | 2004 | 227 | 0.050 |
Why?
|
| Carcinoma | 1 | 2006 | 440 | 0.050 |
Why?
|
| Paclitaxel | 1 | 2005 | 483 | 0.050 |
Why?
|
| Cytarabine | 1 | 2004 | 218 | 0.050 |
Why?
|
| Referral and Consultation | 1 | 2006 | 418 | 0.050 |
Why?
|
| Severity of Illness Index | 1 | 2009 | 2013 | 0.050 |
Why?
|
| Urinary Fistula | 1 | 2002 | 7 | 0.050 |
Why?
|
| Vascular Fistula | 1 | 2002 | 12 | 0.050 |
Why?
|
| Genes, p53 | 1 | 2003 | 108 | 0.050 |
Why?
|
| Fatal Outcome | 1 | 2003 | 296 | 0.050 |
Why?
|
| Diet, Vegan | 1 | 2022 | 1 | 0.050 |
Why?
|
| Suture Techniques | 1 | 2003 | 140 | 0.050 |
Why?
|
| Abdominal Pain | 1 | 2004 | 148 | 0.050 |
Why?
|
| Iliac Artery | 1 | 2002 | 44 | 0.050 |
Why?
|
| Testosterone | 1 | 2024 | 265 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2025 | 2555 | 0.050 |
Why?
|
| Fat Necrosis | 1 | 2002 | 6 | 0.050 |
Why?
|
| Multifactorial Inheritance | 1 | 2025 | 235 | 0.040 |
Why?
|
| Acute Disease | 1 | 2004 | 860 | 0.040 |
Why?
|
| Colonic Diseases | 1 | 2002 | 59 | 0.040 |
Why?
|
| Mice | 4 | 2014 | 12697 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2018 | 889 | 0.040 |
Why?
|
| Life Style | 1 | 2022 | 193 | 0.040 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2021 | 67 | 0.040 |
Why?
|
| Seizures | 1 | 2004 | 324 | 0.040 |
Why?
|
| Urethra | 1 | 2002 | 108 | 0.040 |
Why?
|
| Muscle, Smooth | 1 | 2002 | 299 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2008 | 700 | 0.040 |
Why?
|
| Calcinosis | 1 | 2002 | 220 | 0.040 |
Why?
|
| Chromatin | 1 | 2004 | 454 | 0.040 |
Why?
|
| Cells, Cultured | 2 | 2016 | 2855 | 0.040 |
Why?
|
| Organ Size | 1 | 2021 | 370 | 0.040 |
Why?
|
| Canada | 1 | 2020 | 211 | 0.040 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2019 | 19 | 0.040 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2021 | 304 | 0.040 |
Why?
|
| Kidney Calculi | 1 | 2003 | 357 | 0.040 |
Why?
|
| Radiologic Health | 1 | 2019 | 2 | 0.040 |
Why?
|
| Education | 1 | 2019 | 59 | 0.040 |
Why?
|
| San Francisco | 1 | 2019 | 27 | 0.040 |
Why?
|
| Endpoint Determination | 1 | 2019 | 66 | 0.040 |
Why?
|
| Stents | 1 | 2002 | 433 | 0.040 |
Why?
|
| Diet | 1 | 2022 | 469 | 0.040 |
Why?
|
| Support Vector Machine | 1 | 2019 | 24 | 0.040 |
Why?
|
| Mutation | 3 | 2024 | 4392 | 0.040 |
Why?
|
| Cell Line | 2 | 2018 | 2482 | 0.040 |
Why?
|
| History, 20th Century | 1 | 2020 | 323 | 0.040 |
Why?
|
| CCAAT-Enhancer-Binding Protein-beta | 1 | 2018 | 15 | 0.040 |
Why?
|
| Unnecessary Procedures | 1 | 2019 | 43 | 0.040 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2018 | 62 | 0.030 |
Why?
|
| Ploidies | 1 | 2018 | 39 | 0.030 |
Why?
|
| Mexico | 1 | 2018 | 75 | 0.030 |
Why?
|
| PAX2 Transcription Factor | 1 | 2018 | 6 | 0.030 |
Why?
|
| DEAD Box Protein 58 | 1 | 2018 | 12 | 0.030 |
Why?
|
| Anticoagulants | 1 | 2022 | 486 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 226 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2018 | 81 | 0.030 |
Why?
|
| Poly I-C | 1 | 2018 | 20 | 0.030 |
Why?
|
| Toll-Like Receptor 3 | 1 | 2018 | 16 | 0.030 |
Why?
|
| Heredity | 1 | 2017 | 20 | 0.030 |
Why?
|
| Career Mobility | 1 | 1998 | 39 | 0.030 |
Why?
|
| Radiation Oncology | 1 | 2019 | 130 | 0.030 |
Why?
|
| Epithelium | 1 | 2018 | 316 | 0.030 |
Why?
|
| Quality Control | 1 | 2018 | 130 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2021 | 682 | 0.030 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2004 | 849 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 2022 | 532 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2018 | 370 | 0.030 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2014 | 461 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2018 | 271 | 0.030 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2016 | 20 | 0.030 |
Why?
|
| Social Behavior | 1 | 2019 | 316 | 0.030 |
Why?
|
| Clinical Competence | 2 | 2015 | 865 | 0.030 |
Why?
|
| Patient Preference | 1 | 2018 | 136 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2019 | 321 | 0.030 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2012 | 358 | 0.030 |
Why?
|
| Career Choice | 1 | 1998 | 161 | 0.030 |
Why?
|
| Ligands | 1 | 2018 | 486 | 0.030 |
Why?
|
| Age of Onset | 1 | 2017 | 368 | 0.030 |
Why?
|
| Pain Measurement | 1 | 2018 | 401 | 0.030 |
Why?
|
| Recovery of Function | 2 | 2010 | 370 | 0.030 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2018 | 508 | 0.030 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2019 | 336 | 0.030 |
Why?
|
| Sperm Maturation | 1 | 2015 | 1 | 0.030 |
Why?
|
| Gene Ontology | 1 | 2015 | 38 | 0.030 |
Why?
|
| Pedigree | 1 | 2017 | 980 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2016 | 139 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2009 | 556 | 0.030 |
Why?
|
| Self Report | 1 | 2017 | 355 | 0.030 |
Why?
|
| Molecular Sequence Annotation | 1 | 2015 | 81 | 0.030 |
Why?
|
| Diagnostic Imaging | 1 | 2019 | 467 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2015 | 103 | 0.030 |
Why?
|
| Learning Curve | 1 | 2015 | 25 | 0.030 |
Why?
|
| Keratin-8 | 1 | 2014 | 1 | 0.030 |
Why?
|
| Clusterin | 1 | 2014 | 13 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2015 | 287 | 0.030 |
Why?
|
| London | 1 | 2014 | 15 | 0.030 |
Why?
|
| Apoptosis | 3 | 2007 | 1752 | 0.030 |
Why?
|
| Forearm | 1 | 1994 | 33 | 0.030 |
Why?
|
| Cell Membrane Permeability | 1 | 2014 | 121 | 0.030 |
Why?
|
| Cryotherapy | 1 | 2014 | 31 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2018 | 1153 | 0.030 |
Why?
|
| Ultrasonic Therapy | 1 | 2014 | 44 | 0.030 |
Why?
|
| Cell Polarity | 1 | 2014 | 122 | 0.030 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2014 | 31 | 0.030 |
Why?
|
| Ubiquitination | 1 | 2014 | 80 | 0.030 |
Why?
|
| Electroporation | 1 | 2014 | 61 | 0.030 |
Why?
|
| Heterografts | 1 | 2014 | 121 | 0.020 |
Why?
|
| Critical Pathways | 1 | 2013 | 36 | 0.020 |
Why?
|
| Models, Anatomic | 1 | 2013 | 88 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 256 | 0.020 |
Why?
|
| HIV Infections | 1 | 2003 | 1018 | 0.020 |
Why?
|
| Nitric Oxide | 1 | 1994 | 286 | 0.020 |
Why?
|
| Discriminant Analysis | 1 | 2013 | 64 | 0.020 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2014 | 188 | 0.020 |
Why?
|
| Observer Variation | 1 | 2014 | 579 | 0.020 |
Why?
|
| Internationality | 1 | 2012 | 79 | 0.020 |
Why?
|
| Membrane Glycoproteins | 1 | 2014 | 446 | 0.020 |
Why?
|
| Checklist | 1 | 2013 | 78 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2013 | 340 | 0.020 |
Why?
|
| Postoperative Care | 1 | 2013 | 236 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2017 | 685 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2012 | 282 | 0.020 |
Why?
|
| Computational Biology | 1 | 2016 | 613 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 568 | 0.020 |
Why?
|
| Carcinogenesis | 1 | 2014 | 241 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2014 | 721 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2014 | 1110 | 0.020 |
Why?
|
| Muscles | 1 | 2012 | 179 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2011 | 291 | 0.020 |
Why?
|
| Tissue Culture Techniques | 1 | 2011 | 81 | 0.020 |
Why?
|
| Antioxidants | 1 | 2012 | 236 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2016 | 1133 | 0.020 |
Why?
|
| Stress, Psychological | 1 | 1994 | 383 | 0.020 |
Why?
|
| Cytodiagnosis | 1 | 2011 | 48 | 0.020 |
Why?
|
| Phenotype | 1 | 2017 | 2638 | 0.020 |
Why?
|
| Ureter | 1 | 2011 | 81 | 0.020 |
Why?
|
| Patient Discharge | 1 | 2013 | 381 | 0.020 |
Why?
|
| Constriction | 1 | 2009 | 26 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 360 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2015 | 1646 | 0.020 |
Why?
|
| Digital Rectal Examination | 1 | 2008 | 5 | 0.020 |
Why?
|
| Fibrosis | 1 | 2010 | 234 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2012 | 1950 | 0.020 |
Why?
|
| Observation | 1 | 2008 | 38 | 0.020 |
Why?
|
| Trypsin Inhibitor, Kazal Pancreatic | 1 | 2008 | 6 | 0.020 |
Why?
|
| Education, Medical, Continuing | 1 | 2009 | 100 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2008 | 135 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2009 | 529 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2009 | 731 | 0.020 |
Why?
|
| RNA Interference | 1 | 2008 | 388 | 0.020 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2007 | 76 | 0.020 |
Why?
|
| Lung Diseases | 1 | 2009 | 284 | 0.020 |
Why?
|
| Metals | 1 | 2007 | 104 | 0.020 |
Why?
|
| Transfection | 1 | 2008 | 883 | 0.020 |
Why?
|
| Administration, Intravesical | 1 | 2006 | 40 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2008 | 564 | 0.020 |
Why?
|
| Education, Medical, Graduate | 1 | 2009 | 449 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 2005 | 399 | 0.010 |
Why?
|
| Models, Biological | 1 | 2011 | 1809 | 0.010 |
Why?
|
| Neoplasms, Experimental | 1 | 2005 | 261 | 0.010 |
Why?
|
| Eosinophilia | 1 | 2004 | 87 | 0.010 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2005 | 272 | 0.010 |
Why?
|
| Cystitis, Interstitial | 1 | 2004 | 55 | 0.010 |
Why?
|
| Protein Binding | 1 | 2007 | 1554 | 0.010 |
Why?
|
| Rats | 1 | 2009 | 4072 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2014 | 3621 | 0.010 |
Why?
|
| Cell Survival | 1 | 2005 | 1014 | 0.010 |
Why?
|
| Urologic Surgical Procedures, Male | 1 | 2002 | 19 | 0.010 |
Why?
|
| Gene Silencing | 1 | 2003 | 178 | 0.010 |
Why?
|
| Shock | 1 | 2002 | 56 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2008 | 1255 | 0.010 |
Why?
|
| Autopsy | 1 | 2002 | 131 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2008 | 1717 | 0.010 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2002 | 323 | 0.010 |
Why?
|
| omega-N-Methylarginine | 1 | 1994 | 17 | 0.010 |
Why?
|
| Atropine | 1 | 1994 | 53 | 0.010 |
Why?
|
| Vasodilation | 1 | 1994 | 91 | 0.010 |
Why?
|
| Arginine | 1 | 1994 | 143 | 0.010 |
Why?
|
| Blood Flow Velocity | 1 | 1994 | 179 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 1994 | 194 | 0.010 |
Why?
|